Literature DB >> 9749588

Neuroprotection for Parkinson's disease.

W C Koller1.   

Abstract

Levodopa is the most effective drug available for the treatment of Parkinson's disease (PD). As a precursor of dopamine, levodopa causes an increase in brain dopamine, which is depleted in PD. However, long-term levodopa therapy is associated with complications such as dyskinesias, motor fluctuations, and mental status changes. The treatment of these side effects is a major challenge for the clinician.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9749588     DOI: 10.1002/ana.410440723

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  2 in total

Review 1.  Economic and health-related quality of life considerations of new therapies in Parkinson's disease.

Authors:  L M Rubenstein; A DeLeo; E A Chrischilles
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  Anaesthesia in elderly patients with neurodegenerative disorders: special considerations.

Authors:  Deborah A Burton; Grainne Nicholson; George M Hall
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.